India will have a vaccine of approved corona virus (COVID-19) available within the first quarter of 2021. Also, Serum Institute of India, the world’s largest vaccine manufacturer based on scale, will be in a position to distribute its first vaccine. This information comes from Thursday’s report from a top Wall Street research and brokerage firm, Bernstein Report.
According to the Bernstein Report, there are 4 candidates globally who are close to approval of the vaccine by the end of the current year 2020 or early 2021. Through the partnership, India has two, the first being the AZ / Oxford viral vector vaccine and the AZ / Oxford vaccine with Novavax’s protein sub-unit vaccine. According to the news agency IANS, the report states that SII is best placed to commercialize vaccine candidates with one or both partnerships based on their current capability and competency, given the timing, capacity and pricing of approval.
In the context of data protection of the first stage and trials of the remaining stages of both of these candidates, the vaccine’s ability to elicit an immune response is promising. The report elicits an encouraging response to India’s global capacity equation and hopes to not face challenges to its manufacturing scale.
Price will be 3 dollars
The report says that the Serum Institute can supply 600 million doses in 2021 and 100 million doses in 2022, while Gavi, The Vaccine Alliance and the company’s commitment to the low and middle income markets in India in 2021 Of these doses, 40 to 50 million doses should be available. The report estimates that the vaccine volume between the government and private market will be 55:45. SII has announced that Gavi will pay $ 3 for every dose. The Bernstein Report states that the government is estimated to have a purchase price of $ 3 per dose and for consumers $ 6 per dose.
The report further states that we believe government channels will have access to these capabilities first, but also believe that there will be a large private market for this. In terms of funding, manpower and delivery infrastructure, the government will struggle to bear the burden on its own and we expect the private market to take steps in this direction.
3 other Indian companies are working on the vaccine
The report provides information about 3 other Indian pharma companies apart from SII, which are working on their own vaccine candidates and are currently in Phase I and II. These companies are Zydus Cadila, Bharat Biotech and Biological E. Including SII, Bharat Biotech, Biological E and some smaller companies, India produces around 230 crore doses of various vaccines every year.
Globally, SII is the single largest manufacturer of a vaccine with a capacity of 150 million doses. Globally, 2 out of every 3 children receive a vaccine produced by SII. SII partnered with Gavi the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate the manufacture and delivery of up to 100 million doses of the Corona vaccine for India and Low and Middle Income Countries (LMIC) earlier this August.